rs2061776
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_032447.5(FBN3):c.1201+652G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.177 in 151,950 control chromosomes in the GnomAD database, including 2,731 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.18 ( 2731 hom., cov: 31)
Consequence
FBN3
NM_032447.5 intron
NM_032447.5 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.128
Publications
5 publications found
Genes affected
FBN3 (HGNC:18794): (fibrillin 3) This gene encodes a memebr of the fibrillin protein family. Fibrillins are extracellular matrix molecules that assemble into microfibrils in many connective tissues. This gene is most highly expressed in fetal tissues and its protein product is localized to extracellular microfibrils of developing skeletal elements, skin, lung, kidney, and skeletal muscle. This gene is potentially involved in Weill-Marchesani syndrome. [provided by RefSeq, Mar 2016]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.7).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.252 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FBN3 | ENST00000600128.6 | c.1201+652G>A | intron_variant | Intron 10 of 63 | 1 | NM_032447.5 | ENSP00000470498.1 | |||
FBN3 | ENST00000270509.6 | c.1201+652G>A | intron_variant | Intron 9 of 62 | 1 | ENSP00000270509.2 | ||||
FBN3 | ENST00000601739.5 | c.1201+652G>A | intron_variant | Intron 10 of 63 | 1 | ENSP00000472324.1 | ||||
FBN3 | ENST00000651877.1 | c.1327+652G>A | intron_variant | Intron 10 of 63 | ENSP00000498507.1 |
Frequencies
GnomAD3 genomes AF: 0.177 AC: 26922AN: 151832Hom.: 2731 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
26922
AN:
151832
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.177 AC: 26939AN: 151950Hom.: 2731 Cov.: 31 AF XY: 0.173 AC XY: 12885AN XY: 74266 show subpopulations
GnomAD4 genome
AF:
AC:
26939
AN:
151950
Hom.:
Cov.:
31
AF XY:
AC XY:
12885
AN XY:
74266
show subpopulations
African (AFR)
AF:
AC:
10612
AN:
41416
American (AMR)
AF:
AC:
2061
AN:
15250
Ashkenazi Jewish (ASJ)
AF:
AC:
416
AN:
3468
East Asian (EAS)
AF:
AC:
8
AN:
5176
South Asian (SAS)
AF:
AC:
366
AN:
4818
European-Finnish (FIN)
AF:
AC:
1724
AN:
10550
Middle Eastern (MID)
AF:
AC:
33
AN:
292
European-Non Finnish (NFE)
AF:
AC:
11294
AN:
67970
Other (OTH)
AF:
AC:
318
AN:
2098
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
1089
2177
3266
4354
5443
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
288
576
864
1152
1440
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
170
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.